![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biotest AG | TG:BIO | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 41.60 | 41.60 | 42.40 | 0.00 | 14:18:06 |
RNS Number:4589U BioFocus PLC 21 January 2004 For Immediate Release 21 January 2004 BIOFOCUS plc TRADING UPDATE - MEETS MARKET EXPECTATIONS BioFocus plc announces today a trading update for the 12 months ended 31 December 2003. The Company expects its turnover and profit before amortisation of goodwill and exceptional items to be within the range of market expectations. Strong performance from the discovery products division and income from technology access fees offset subdued demand for fee for service business. The SoftFocusTM brand of compound libraries demonstrated its position as a market leader, attracting orders from several major pharmaceutical companies. The Company's financial strength improved during 2003, with unaudited year-end cash balances in excess of #4m (2002: #3.5m). There has been an encouraging start to 2004 and the company is presently negotiating new collaborations. The closure of the Sittingbourne operations was completed by the end of 2003, on time and within budget. Staff have been relocated and the new offices and laboratories at Chesterford Park are now fully operational. It is hoped that a surrender of the lease on the Sittingbourne premises will be agreed in the next few months. 2003 was a difficult year for the industry but BioFocus is pleased with its trading performance and the successful management of various changes to the business during the year. The Company is now well placed with its mix of collaborations, programmes, products and in-house drug discovery, to take advantage of the improvement in market conditions. -ENDS- For further information, please contact: BioFocus plc 01799 533500 Geoff McMillan - Chief Executive Stephen France - Finance Director Buchanan Communications 020 7466 5000 Tim Anderson/Rebecca Skye Dietrich About BioFocus BioFocus works in partnership with major pharmaceutical and biotechnology companies. It is also developing its own portfolio of internal drug discovery programmes aimed at providing drug leads for partnering. The company was founded in 1997 and is quoted on the Alternative Investment Market of the London Stock Exchange. Clients include Amgen, GSK, Roche and Teijin. This information is provided by RNS The company news service from the London Stock Exchange END TSTEANFEADLLEFE
1 Year Biotest Chart |
1 Month Biotest Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions